# NCT03793166 (NCT03793166)

> Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03793166
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: National Cancer Institute (NCI)
- Conditions: Clear Cell Renal Cell Carcinoma; Metastatic Malignant Neoplasm in the Bone; Metastatic Malignant Neoplasm in the Lymph Nodes; Metastatic Malignant Neoplasm in the Soft Tissue; Metastatic Malignant Neoplasm in the Viscera; Rhabdoid Tumor of the Kidney; Sarcomatoid Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8
- Interventions: Biospecimen Collection; Bone Scan; Cabozantinib; Computed Tomography; Ipilimumab; Magnetic Resonance Imaging; Nivolumab; Quality-of-Life Assessment; Questionnaire Administration
- Enrollment: 1175
- Primary outcome: Overall survival (OS)

## Indexed commentary on NCT03793166 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 2
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct03793166